Patents by Inventor Yasemin Suezer

Yasemin Suezer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA)-BASED VACCINE FOR THE AVIAN FLU
    Publication number: 20110020391
    Abstract: The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament in particular a vaccine, wherein the sequence of heterologous nucleic acid is from influenza A virus class H5 antigen. In a further aspect of the invention the invention relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein (a) the heterologous nucleic acid is incorporated into a non-essential site within the genome of MVA, (b) the heterologous nucleic acid is under the control of a vaccinia virus promoter, or orthopoxvirus promoter, or poxvirus-specific promoter and, (c) the heterologous nucleic acid is selected from the group of nucleic acids encoding a gene or a part of a gene from an influenza A virus class H5.
    Type: Application
    Filed: November 16, 2007
    Publication date: January 27, 2011
    Applicant: PAUL-EHRLICH-INSTITUT BUNDESAMT FUR SERA UND IMPFSTOFFE
    Inventors: Yasemin Süzer, Johannes Löwer, Gerd Sutter, A.D.M.E. Osterhaus, G.F Rimmelzwaan, Joost Kreijtz
  • USE OF RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA (MVA) FOR THE TREATMENT OF TYPE 1 HYPERSENSITIVITY IN A LIVING ANIMAL INCLUDING HUMANS
    Publication number: 20090191157
    Abstract: The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament for the prevention and/or treatment of type I hypersensitivity in a living animal including humans. The invention further relates to a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid, wherein the heterologous nucleic acid is incorporated into a non-essential region of the genome of the MVA, the heterologous nucleic acid is under the control of, e.g. a vaccinia virus-specific promoter and, the heterologous nucleic acid is selected from the group of nucleic acids encoding an allergen selected from the group of weed pollens, grass pollens, tree pollens, mites, animals, fungi, insects, rubber, worms, human autoallergens, and foods.
    Type: Application
    Filed: March 14, 2007
    Publication date: July 30, 2009
    Applicant: PAUL-ENRLICH-INSTITUT BUNDESAMT FUER SERA UND IMPFSTOFFE
    Inventors: Melanie Albrecht, Gerd Sutter, Yasemin Suezer, Gerald Reese, Stefan Vieths, Caroline Staib